|
 |
Gliadel WaferThis page contains recent news articles, when available, and an overview of Gliadel Wafer but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Gliadel Wafer (when available) Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that Carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. Mechanism Of Action: Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death. News Articles on Carmustine Gliadel(R) Wafer Demonstrates Long-Term Survival Benefit for Patients... - Mar 8, 2006 Gliadel Wafer is approved by the FDA for treatment of patients with newly-diagnosed ... Gliadel Wafer is also indicated to treat recurrent glioblastoma ... Free with registration - Business Wire - AccessMyLibrary.com Gliadel® Wafer Plus Temozolomide Show Promising Results in High … - May 18, 2005 By Guilford Pharmaceuticals Inc., [RxPG] Guilford Pharmaceuticals Inc. today announced findings from a study of GLIADEL(R) Wafer (polifeprosan 20 with ... RxPG NEWS US FDA says MGI Pharma tumor therapy ad misleading - Jan 31, 2007 A two-page promotional ad for the product, called gliadel wafer, ... In one instance the ad states "Gliadel wafer works at day 1" but does not say the claim ... Reuters Gliadel(R) Wafer Clinical Data Presented at Society for Neuro... - Nov 20, 2006 Patients underwent craniotomy and Gliadel Wafer implantation (7.7 mg carmustine per wafer), ... Gliadel Wafer (polifeprosan 20 with carmustine implant) is a ... Free with registration - PR Newswire - AccessMyLibrary.com Ranbaxy inks deal with BioPro Pharmaceutical - Dec 3, 2008 The company has also received the import permission for marketing the USFDA approved drug 'GLIADEL Wafer'in India, Ranbaxy said. Gliadel Wafer is the only ... Hindu Business Line Gliadel(R) Wafer Clinical Data Presented At Society For Neuro... - Nov 21, 2006 Patients underwent craniotomy and Gliadel Wafer implantation (7.7 mg carmustine per wafer), ... Gliadel Wafer (polifeprosan 20 with carmustine implant) is a ... Medical News Today - Medical News Today (press release) NeoPharm takes turn for worse: Brain cancer drug tests a major … - Dec 12, 2006 30.1 percent for patients on Gliadel Wafer at 12 months, 20 percent vs. 14.5 percent at 18 months and 14.4 percent vs. 14.5 percent at 24 months. ... $2.95 - Chicago Sun-Times - NewsBank Eisai Agrees to Buy MGI Pharma for $3.9 Billion (Correct) - Dec 11, 2007 ...``These offerings, especially with something like the Gliadel Wafer, which is very novel, will compliment Eisai.'' Eisai bought US biotechnology company ... Bloomberg Brain Cancer; New GLIADEL Wafer data presented at SNO meeting - Jan 1, 2005 2005 JAN 1 - (NewsRx.com & NewsRx.net) -- Guilford Pharmaceuticals, Inc., (GLFD) announced that new data for GLIADEL Wafer (polifeprosan 20 with carmustine ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Novel glioblastoma therapy holds promise - Jan 21, 2008 The dual implantation of Gliadel Wafer and radioactive seeds was well tolerated among ... Gliadel Wafer is made by US biopharmaceutical company MGI Pharma. Pharmacy Europe Press Release: Gliadel(R) Wafer Clinical Data Presented at Society... - Nov 20, 2006 MGI PHARMA expects that Gliadel Wafer will be complementary with the ... and ... MGI PHARMA anticipates that fourth quarter Gliadel Wafer sales will ... Pay-Per-View - PR Newswire - HighBeam Research Guilford Pharmaceuticals sees positive safety data for its Gliadel... - May 23, 2005 Guilford Pharmaceuticals, a US neurology specialist drugmaker, says that a study of its brain cancer adjuvant therapy, Gliadel Wafer (polifeprosan 20 with ... $4.95 - Pharma Marketletter - ECNext Gliadel(R) Wafer Demonstrates Long-term Survival Benefit For Patients... - Mar 11, 2006 Gliadel Wafer is approved by the FDA for treatment of patients with newly-diagnosed ... Gliadel Wafer is also indicated to treat recurrent glioblastoma ... Medical News Today - Medical News Today (press release) DA Consortium Inc acquires a minority stake in Ergo-Brains Inc - Deal... - Jun 20, 2005 Phase Source Partner Gliadel Wafer Brain Tumor M Hexalen Ovarian Cancer…Gliadel Wafer with iodine-### Brain Tumor II ZYC### Solid Tumors… ... Pay-Per-View - deals - Alacra Store Implanted Wafer Helps Fight Brain Cancer - Mar 17, 2006 In the United States, the "Gliadel Wafer" is currently approved for ... That study found that patients treated with Gliadel Wafer in combination with ... HealthCentral.com City biotech sold to MGI Pharma for $177 million ; Guilford … - Jul 22, 2005 ...along with a marketed brain cancer treatment, called the Gliadel Wafer, to add to its oncology portfolio. With Guilford, MGI will also acquire debt - nearly ... Pay-Per-View - The Sun - ProQuest Archiver THE TUMOR TEAM - Jun 10, 2008 One older treatment still in use is the Gliadel wafer, a tiny disk made of dried ... It is not clear whether Kennedy received a Gliadel wafer during his ... $2.95 - Miami Herald - NewsBank MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals. - Oct 3, 2005 MGI PHARMA expects that Gliadel Wafer will be complementary with the Company's ... MGI PHARMA anticipates that fourth quarter Gliadel Wafer sales will ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Announces Results from Study Involving the Dual … - Jan 18, 2008 The dual implantation of Gliadel Wafer and radioactive seeds was well-tolerated among patients and may contribute to longer survival than when surgery is ... Genetic Engineering News - Genetic Engineering News (press release) GLIADEL Wafer MGI Pharma clinical data (phase II) (glioma). - Dec 4, 2006 On 20 November 2006 MGI Pharma reported interim results from a phase II trial of GLIADEL Wafer and temozolomide, in combination with surgery and ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones DA Consortium Inc acquires a minority stake in Ergo-Brains Inc... - Feb 16, 2006 Phase Source Partner Gliadel Wafer Brain Tumor M Hexalen Ovarian Cancer…Gliadel Wafer with iodine-### Brain Tumor II ZYC### Solid Tumors… ... Pay-Per-View - deals - Alacra Store NeoPharm drug fails test: Cancer therapy bust sends stock into dive. - Dec 12, 2006 In the trial involving about 300 patients, about two-thirds received IL-13 and the remaining one-third received Gliadel Wafer, the standard chemotherapy ... Free with registration - Chicago Tribune - AccessMyLibrary.com Positive data on MGI Pharma's Gliadel. - Jan 28, 2008 The dual implantation of Gliadel Wafer and radioactive seeds was well-tolerated among patients and may contribute to longer survival than when surgery is ... Free with registration - Pharma Marketletter - AccessMyLibrary.com NeoPharm Announces PRECISE Trial Has Reached Criteria for Interim … - Jun 8, 2006 A Gliadel Wafer delivers BCNU (known as carmustine), a commonly used ... A post hoc analysis of the Gliadel Wafer data for favorable prognostic factors did ... Free with registration - Business Wire - AccessMyLibrary.com Orphan drugs moving ahead ; Focus: Their development is a fast... - Aug 28, 2005 A manager at Guilford Pharmaceuticals holds a Gliadel Wafer orphan drug used in cancer treatment. 4. OvaRex, which is in a Phase III clinical trial, ... Pay-Per-View - The Sun - ProQuest Archiver NeoPharm plunges 68% after drug misses target - Dec 11, 2006 The median survival time for NeoPharm's drug was 36.4 weeks, compared with 35.3 weeks for Gliadel Wafer. "Topline data suggests that cintredekin besudotox, ... Crain's Chicago Business Cancer Research; US FDA approves special protocol assessment for … - Sep 20, 2005 ...data monitoring committee (DMC), after notification of 160 deaths to demonstrate potential superiority of cintredekin besudotox over Gliadel Wafer. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: BHIP, CADX, MOGN, WEESF, TFZP Have Also Been … - Jan 24, 2008 MGI PHARMA markets Aloxi Injection ... Gliadel Wafer in the United States. The Company directly ... more information about MGI PHARMA, please visit www ... ... Pay-Per-View - M2 Presswire - HighBeam Research Loislaw Federal District Court Opinions - WILDER v. GUILFORD … - Jul 7, 2006 The Gliadel Wafer is primarily used by neurosurgeons, oncologists and ... During the period that plaintiff sold the Gliadel Wafer, Michael Least was her ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Q4 2004 Neopharm Earnings Conference Call - Final. - Feb 24, 2005 In other words, 200 patients will receive Cintredekin Besudotox and 100 patients will receive the Gliadel Wafer. Once the trial is fully enrolled, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com MGI Pharma hires bankers to examine its options - Nov 29, 2007 MGI's products include Aloxi, a treatment to prevent chemotherapy-induced nausea, Gliadel Wafer, a drug delivery device in the treatment of brain cancer, ... Reuters Wilder v. Guilford Pharmaceutical Products, Inc., No. 2:04-CV-1199 ( … - Jul 7, 2006 The Gliadel Wafer is primarily used by neurosurgeons, oncologists and neurooncologists. ... [11], During the period that plaintiff sold the Gliadel Wafer, ... $2.95 - U.S. District Court, Southern District... - VersusLaw Carmustine Implant Improves Malignant Glioma Survival - Mar 29, 2006 NEW YORK MAR 29, 2006 (Reuters Health) - Placement of a biodegradable polymer containing 3.85% carmustine, the Gliadel wafer (MGI PHARMA) in the resection ... Cancerpage.com Gloucester Pharmaceuticals Strengthens Management Team in Key … - Aug 25, 2005 Gliadel Wafer(R) is a trademark of Guilford Pharmaceuticals. This press release contains forward-looking statements concerning Gloucester that involve a ... $4.95 - Business Wire - ECNext Article: NeoPharm takes turn for worse: Brain cancer drug tests a... - Dec 12, 2006 Median survival was 36.4 weeks for patients treated with cintredekin besudotox, compared with 35.3 weeks for those treated with the Gliadel Wafer. ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Local Focus.(Business) | Article from Daily Herald (Arlington... - May 26, 2005 ...improvement in the median survival rate of patients treated with the Gliadel Wafer, a current treatment approved by the Food and Drug Administration. ... Pay-Per-View - Daily Herald - HighBeam Research Article: Fighting brain tumours: revolutionary therapy.(PRODUCTS & … - Mar 1, 2005 The proprietary Gliadel wafer contains a precise amount of the ... A recent clinical study of the Gliadel wafer treatment has been conducted at 38 hospitals ... Pay-Per-View - African Business - HighBeam Research BANKING Bank of America to Ki ... | Article from The Washington Post... - Dec 11, 2007 The deal, to be completed by March, would give Eisai, of Tokyo, access to more cancer drugs, including Aloxi, Hexalen and the Gliadel Wafer. ... Pay-Per-View - Washington Post - HighBeam Research Market Live from BSE - NSE, Latest Market Commentary | Economic … - Dec 3, 2008 Ranbaxy has signed an exclusive licensing agreement with BioPro Pharmaceutical Inc, US to promote and market Gliadel wafer in India. ... Economic Times Article: Qld: Scientists find potential brain cancer treatment - AAP... - Dec 7, 2006 Gliadel wafer for treating brain cancer, and its Aggrastat heart ... Gliadel wafer-treatment for brain cancer, the firm also bulked up its ... ... Pay-Per-View - AAP General News - HighBeam Research NeoPharm Announces First Quarter 2006 Financial Results - Apr 23, 2006 The PRECISE protocol does not require cintredekin besudotox to show a predetermined improvement in median survival over Gliadel Wafer(R). ... businesswire.com MGI Pharma at Lehman Brothers Ninth Annual Global Healthcare … - Mar 10, 2006 And they will be also carrying the Aloxi franchise, Gliadel Wafer, DacogenTM in the hospital setting and getting prepared for the oncoming Aquavan and Aloxi ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com NeoPharm Announces First Quarter 2006 Financial Results - May 5, 2006 The PRECISE protocol does not require cintredekin besudotox to show a predetermined improvement in median survival over Gliadel Wafer(R). ... Genetic Engineering News - Genetic Engineering News (press release) CORRECTING and REPLACING NEOPHARM Announces Second … - Jun 30, 2006 The PRECISE protocol does not require CINTREDEKIN BESUDOTOX to show a predetermined improvement in median survival over Gliadel Wafer(R). ... businesswire.com Eisai to buy US drug maker for $3.9B | Article from The Record... - Dec 11, 2007 MGI, based in Bloomington, Minn., sells Aloxi shots for chemotherapy-induced nausea; the Gliadel Wafer, a biodegradable wafer with a chemotherapy agent; ... Pay-Per-View - The Record - HighBeam Research NEOPHARM Provides Update on Reimbursement Progress for … - Aug 7, 2006 Patients were randomized so that 2 patients received CINTREDEKIN BESUDOTOX via CED for every 1 patient that received Gliadel Wafer placed in the resection ... $4.95 - Business Wire - ECNext NEOPHARM Announces Second Quarter 2006 Financial Results. - Aug 9, 2006 The PRECISE protocol does not require CINTREDEKIN BESUDOTOX to show a predetermined improvement in median survival over Gliadel Wafer(R). ... $4.95 - Business Wire - ECNext The Next Generation of Drug-Delivery Microdevices - Nov 3, 2008 Both the Gliadel wafer and the device designed by Grayson et al. offer first-generation modalities for polymer-based passive drug delivery from multiple ... Nature.com Article: MEMC wins patent fight in Europe. - St. Louis Post-Dispatch... - Oct 19, 2005 Article: GLIADEL Wafer maker reports Q3 net loss of $14.5 ... Life Science Weekly; December 7, 2004 ; 700+ words ...2004 DEC 7 - (NewsRx.com & NewsRx.net) ... Pay-Per-View - St. Louis Post-Dispatch - HighBeam Research NeoPharm names new CEO - Mar 27, 2007 ...did not have significantly different survival rates than patients on MGI Pharma Inc.'s Gliadel Wafer treatment, the current standard treatment. ... $2.95 - Chicago Sun-Times - NewsBank Article: Goeman, Scott J. - The Milwaukee Journal Sentinel | HighBeam... - May 16, 2008 Gliadel wafer for treating brain cancer, and its Aggrastat heart ... wafer-treatment for brain cancer, the firm also bulked ... for Janney Montgomery Scott ... Pay-Per-View - Milwaukee Journal Sentinel - HighBeam Research US BANCORP SELLS DEBT TO FUND STOCK BUYBACK - Feb 1, 2007 The two-page promotional ad for the company's Gliadel Wafer product failed to disclose the full indication for the drug, and presented unsubstantiated ... $2.95 - St. Paul Pioneer Press - NewsBank Health Stocks in Motion - Aug 24, 2005 ...will be conducted after notification of 160 deaths to demonstrate potential superiority of cintredekin besodotox over Gliadel wafer. ... TheStreet.com - TheStreet.com (subscription) MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial … - Feb 7, 2007 Sales of Gliadel Wafer were $8.2 million for the fourth quarter of 2006, compared to $8.5 million in the fourth quarter of 2005. For the year ended December ... Genetic Engineering News - Genetic Engineering News (press release) Drug stocks slip; Nuvelo, Neopharm plunge - Dec 11, 2006 Gliadel Wafer, made by MGI Pharma Inc. (TSE:JP:4523). Neopharma shares gave back $4.56, or 68%, to close at $2.16; MGI shares added 18 cents to end at ... MarketWatch MGI Loses Less Than Expected - Apr 19, 2006 Sales of MGI's Gliadel Wafer brought in $9.7 million vs. $7.3 million last year. In the second quarter, MGI expects to hear from the Food and Drug ... TheStreet.com - TheStreet.com (subscription) MGI Pharma Misses Targets - Feb 8, 2006 ...in the range of $370 million to $385 million, including Aloxi injection sales of $285 million to $300 million, and Gliadel Wafer sales of $40 million. ... TheStreet.com - TheStreet.com (subscription) Helsinn and MGI Pharma announce sNDA for ALOXI Capsules accepted … - Mar 1, 2008 LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare SA, Switzerland, a privately owned pharmaceutical group and its partner, ... presseportal.ch MEDICINE; IN THE LAB; Brain cancer in its sights; An experimental... - Aug 15, 2005 Two hundred patients will receive one treatment of IL13-PE38QQR, while the remainder will be treated with a Gliadel wafer, an anti-cancer drug that is ... Pay-Per-View - Los Angeles Times - ProQuest Archiver MGI Paying $45M Up Front For Thrombocytopenia Drug - Aug 30, 2007 ...hydrochloride) for chemotherapy-induced nausea and vomiting, and Gliadel Wafer (polifeprosan 20 with carmustine implant) for malignant glioma. ... BioWorld Online - BioWorld Online Neopharm encouraged by tumor drug trial - Apr 27, 2006 ...survival for the 45 patients in the study was 44 weeks, compared with 28 weeks with currently available chemotherapy treatment known as Gliadel Wafer. ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Interim CEO on Neopharm's short list for permanent post - Jun 30, 2005 On the current existing treatment known as Gliadel Wafer, median survival is 28 weeks, which means Neopharm's IL-13 has to improve median survival to 42 ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Neopharm cutting 20 jobs to save cash - May 2, 2006 ...survival time of 45 patients in one study was 44 weeks, compared with 28 weeks with currently available chemotherapy treatment known as Gliadel Wafer. ... Pay-Per-View - Chicago Tribune - ProQuest Archiver GLFD Implements Restructuring Plan - May 24, 2005 Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) implemented a restructuring plan to reduce overall costs focus on key assets, GLIADEL Wafer and AQUAVAN ... StreetInsider.com - StreetInsider.com (subscription) Biotech lays off 38 in cost cutting measure. - May 25, 2005 The new strategy included unloading heart-attack treatment Aggrastat, which has been draining resources, and putting more emphasis on its Gliadel wafer, ... Free with registration - Baltimore Sun - AccessMyLibrary.com Guilford Pharmaceuticals' overhaul plans met with skepticism on stock... - Apr 7, 2005 Instead, Guilford will build the company around two products: its Gliadel Wafer, which treats brain cancer, and Aquavan, a light sedative in its third phase ... Free with registration - Baltimore Sun - AccessMyLibrary.com MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Jul 9, 2007 MGI PHARMA, INC. (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned ... RedOrbit MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Mar 4, 2008 MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN ... businesswire.com Chemo wafers helping brain cancer patients live a better life - Mar 4, 2007 Studies have shown that on patients with recurrent tumors, Gliadel Wafer treatment adds an average of 2.6 months to their lives. ... sptimes.com Pituitary Tumors - May 31, 2005 Implantation of the GLIADEL wafer serves two important purposes. First, the drug is released into the area of the tumor, hopefully killing remaining tumor ... WOWT Guilford halts drug trial ; Baltimore biotech's stock down 34% in... - Mar 25, 2005 Its two marketed drugs - the Gliadel Wafer, a brain cancer treatment, and the Aggrastat Injection, used to treat heart attack patients - had combined sales ... Pay-Per-View - The Sun - ProQuest Archiver Some executives are leaving much bigger pharmaceutical companies for ... - Apr 21, 2005 Guilford has been struggling over the past few years, missing marketing opportunities for its Gliadel wafer, a brain cancer treatment, and dealing with ... Pay-Per-View - The Sun - ProQuest Archiver NeoPharm cuts 20% of jobs: Cancer drug's failure ripples through … - Dec 27, 2006 ...were not significantly different than the survival rates of patients on MGI Pharma Inc.'s Gliadel Wafer treatment, the current standard treatment. ... $2.95 - Chicago Sun-Times - NewsBank Article: Thomas continues to play through 2nd brain tumor.(Virginia... - Jun 4, 2006 GLIADEL Wafer is designed ... treat of all cancers," said Thomas Grahm, MD, Tyler Neurosurgical ... Business Wire. Article: Alkermes expands RMP-7 brain ... Pay-Per-View - Virginian-Pilot - HighBeam Research CHS PROFIT NEARLY DOUBLES IN FISCAL 2006 - Nov 23, 2006 MGI's Gliadel Wafer, which releases a chemotherapy agent for the treatment of highly malignant brain tumors, was found to extend patients' survival rate to ... $2.95 - St. Paul Pioneer Press - NewsBank NEOPHARM Reports Fourth-Quarter and Full-Year 2006 Financial … - Mar 13, 2007 ...which was a statistically significant difference, or separation, in the overall survival curves versus the Gliadel Wafer([R]), or Gliadel. ... Free with registration - Business Wire - AccessMyLibrary.com USA pharma: FDA approves Eisai sedative in limited setting - Dec 16, 2008 Aquavan was one of the top drugs in Guilford's pipeline, along with the marketed cancer drug Gliadel Wafer (polifeprosan 20 with carmustine implant). ... $34.00 - EIU Country Analysis - Alacra Store MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection Sales … - Dec 31, 2006 Total sales of Gliadel Wafer were approximately $34 million (unaudited) in 2005, a 22% increase over 2004 sales. -- Oncology franchise: Highlighted by ... businesswire.com Market Commentary on NeoPharm Inc. - Dec 11, 2006 The company said it was evaluating cintredekin besudotox for the treatment of recurrent glioblastoma mulitforme against Gliadel Wafer, which is implanted in ... Free with registration - M2 Presswire - AccessMyLibrary.com Targepeutics Actively Developing Targeted Molecular Therapies for … - Jan 4, 2007 ...(Cintredekin Besudotox) was at least as potent as MGI Pharma's Gliadel Wafer in patients with treatment- resistant recurrent high-grade astrocytoma. ... Free with registration - PR Newswire - AccessMyLibrary.com Reports Activity for MGI PHARMA INC. - Oct 19, 2006 ...the commercial launch of Dacogen(TM) (decitabine) for Injection, and the inclusion of sales of Gliadel Wafer (polifeprosan 20 with carmustine implant) ... Free with registration - M2 Presswire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere MGI PHARMA Third Quarter 2007 Financial Results Conference Call to … - Oct 17, 2007 MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN) will webcast its third quarter 2007 financial results conference call with investors live over ... businesswire.com Neopharm Clears a Key Hurdle: Brain Cancer Drug Advances, Takes … - Dec 28, 2005 Using the current existing treatment known as Gliadel Wafer, median survival is 28 weeks, which means Neopharm's IL-13 has to improve median survival to 42 ... RedOrbit MGI Pharma provides '06 sales guidance - Jan 10, 2006 Sales of Gliadel Wafer, a brain tumor treatment acquired in MGI Pharma's purchase of Guilford Pharmaceuticals in October, rose 22 percent to $34 million in ... Twin Cities Business Journal Guilford expects profit in '08 - Apr 6, 2005 Sales of Guilford's brain cancer drug, the Gliadel wafer, is also critical to its ability to reach profitability, Mitchell said. ... Baltimore Business Journal Baltimore-Based Guilford Pharmaceuticals Inc. Gives MGI Pharma Local ... - Oct 3, 2005 Guilford's lead product is the Gliadel wafer, a treatment for brain cancer, which brought in $8.5 million in net sales during the quarter ended June 30. ... RedOrbit Guilford's growth yields wider loss - Mar 2, 2005 Sales of Guilford's Gliadel wafer, used to treat brain cancer, rose 44 percent to $27.7 million from $8.5 million in 2003, which the company credits to the ... Baltimore Business Journal Advanced Drug Delivery Systems: New Development, New Technologies - Oct 1, 2006 ...eg, the acquisition of Guilford Pharmaceuticals by MGI Pharma, which added Gliadel Wafer (polifeprosan 20 with carmustine implant) to its portfolio. ... MarketResearch.com Brain cancer therapy.(Therapeutic vaccine) - Jul 30, 2007 ...hair loss and neurotoxicity, associated with conventional chemotherapy drugs, including Temodar (Schering-Plough) and Gliadel Wafer (MGI Pharma). ... Free with registration - Chemistry and Industry - AccessMyLibrary.com Targepeutics Actively Developing Targeted Molecular Therapies For … - Jan 7, 2007 ...(Cintredekin Besudotox) was at least as potent as MGI Pharma's Gliadel Wafer in patients with treatment- resistant recurrent high-grade astrocytoma. ... Medical News Today - Medical News Today (press release) MGI PHARMA Third Quarter 2006 Financial Results Conference Call to … - Oct 18, 2006 MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN) will broadcast its third quarter 2006 financial results conference call with investors live ... businesswire.com StreetInsider.com Unusual 11 Mid-Day Movers 12/11/06 - Dec 11, 2006 ...efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer. ... StreetInsider.com - StreetInsider.com (subscription) NeoPharm.(Phase III) - Jan 1, 2007 ...glioblastoma multiforme, did not meet its efficacy endpoint--there was no statistically significant difference in overall survival versus Gliadel Wafer. ... Free with registration - Applied Clinical Trials - AccessMyLibrary.com Guilford Mulls Dosing Plan For Phase III With Aquavan - Mar 28, 2005 Guilford has two marketed products - Gliadel Wafer, which is polifeprosan 20 with carmustine implant for brain cancer, and Aggrastat (tirofiban ... BioWorld Online - BioWorld Online MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the … - Sep 1, 2005 For additional prescribing information about Gliadel wafer and Aggrastat injection please see http://www.guilfordpharm.com. ... $4.95 - Business Wire - ECNext Company Profile Report - Jan 26, 2008 Alkylating Agents. Nitrosoureas. Products:. Gliadel Wafer (Polifeprosan 20 With Carmustine Implant). Phase I/Phase II Clinical Stage Products. Products: ... $50.00 - Revere Reports - Revere Guilford loses 20% of workforce over Gliadel.(pharmaceutial industry)(... - Jun 6, 2005 ...focusing its efforts on sales of its flagship product, the brain cancer drug, Gliadel Wafer (polifeprosan 20 with carmustine implant), and the clinical ... $4.95 - Pharma Marketletter - ECNext Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere Press Release: Consolidated Sales of 372.0 Million Euros and Growth... - Apr 16, 2007 Article: Gliadel Wafer sales increase; company reports net ... Health & Medicine Week; September 1, 2003 ; 700+ words ...2003 SEP 1 - (NewsRx.com ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Gliadel Wafer is also known by the following brand names and/or synonymsBCNU; Becenun; Bi Cnu; Bicnu; Bischlorethylnitrosourea; Bischlorethylnitrosurea; Carmubris; Carmustin; Carmustine; FDA 0345; Gliadel; Gliadel Wafer; Nitrumon; SRI 1720 Drug Category: Gliadel Wafer is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01AD01 Dosage Forms: 100 mg single dose vials of lyophilized material Absorption: 5 to 28% bioavailability Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: N-(2-chloroethyl)-1-(2-chloroethylamino)-N-nitroso-methanamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |